Vicus is employing immunotherapy to selectively target signaling pathways that lead to tumor-promoting inflammation and tumor evasion of the immune system. Our goal is to safely and significantly extend the clinical benefit of proven targeted cancer therapies.
We are an immuno-oncology company developing breakthrough immunotherapies for patients with solid-tumor cancers. We are focused on the development and commercialization of our lead product candidate, VT-122, a immunotherapy for advanced liver cancer patients receiving sorafenib and for pre-chemo prostate cancer patients receiving androgen inhibition therapies.
September 8, 2014: Vicus Therapeutics Announces Phase II Data Demonstrating Overall Survival Benefit with VT-122 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma